Understanding internalization of rotavirus VP6 nanotubes by cells: towards a recombinant vaccine
Rotavirus VP6 nanotubes are an attractive option for a recombinant vaccine against rotavirus disease. Protection against rotavirus infection and an adjuvant effect have been observed upon immunization with VP6 nanotubes. However, little information exists on how VP6 nanotubes interact with cells and trigger an immune response. In this work, the interaction between VP6 nanotubes and different cell lines was characterized. VP6 nanotubes were not cytotoxic to any of the animal or human cell lines tested. Uptake of nanotubes into cells was cell-line-dependent, as only THP1 and J774 macrophage cells internalized them. Moreover, the size and spatial arrangement of VP6 assembled into nanotubes allowed their uptake by macrophages, as double-layered rotavirus-like particles also displaying VP6 in their surface were not taken up. The internalization of VP6 nanotubes was inhibited by methyl-β-cyclodextrin, but not by genistein, indicating that nanotube entry is specific, depends on the presence of cholesterol in the plasma membrane, and does not require the activity of tyrosine kinases. The information generated here expands our understanding of the interaction of protein nanotubes with cells, which is useful for the application of VP6 nanotubes as a vaccine.
KeywordsGenistein THP1 Cell Recombinant Vaccine J774 Cell J774 Macrophage
Financial support was provided by SEP-Conacyt 101847 and PAPIIT-UNAM IN223210 and IT200113. MR received financial support from Conacyt during her graduate studies. Technical support was provided by A. R. Pastor and V. Hernández and by G. Zavala and A. N. Lecona at the Electron Microscopy Units of Instituto de Biotecnología UNAM and Instituto Nacional de Salud Pública, Mexico, and J. A. Pimentel at the Laboratorio Nacional de Microscopía Avanzada UNAM, México. Materials were provided by Dr. Y. Rosenstein, Dr. A. Valdez, and Dr. C. Treviño.
Conflict of interest
The authors declare that they do not have any direct financial relationship with the commercial entities mentioned in this manuscript.
- 2.Rotavirus vaccines WHO position paper: January 2013—Recommendations (2013). Vaccine. doi: 10.1016/j.vaccine.2013.05.037
- 8.Corthesy B, Benureau Y, Perrier C, Fourgeux C, Parez N, Greenberg H, Schwartz-Cornil I (2006) Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. J Virol 80(21):10692–10699. doi: 10.1128/JVI.00927-06 PubMedCentralPubMedCrossRefGoogle Scholar
- 9.McNeal MM, VanCott JL, Choi AH, Basu M, Flint JA, Stone SC, Clements JD, Ward RL (2002) CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G). J Virol 76(2):560–568PubMedCentralPubMedCrossRefGoogle Scholar
- 10.Smiley KL, McNeal MM, Basu M, Choi AH, Clements JD, Ward RL (2007) Association of gamma interferon and interleukin-17 production in intestinal CD4+ T cells with protection against rotavirus shedding in mice intranasally immunized with VP6 and the adjuvant LT(R192G). J Virol 81(8):3740–3748. doi: 10.1128/JVI.01877-06 PubMedCentralPubMedCrossRefGoogle Scholar
- 14.Pastor-Flores AR Rodríguez-Limas WA, Contreras MA, Esquivel-Soto E, Esquivel-Guadarrama F, Ramírez OT, Palomares LA (2013) The assembly conformation of rotavirus VP6 determines its protective efficacy against rotavirus challenge in mice. Vaccine (in press)Google Scholar
- 16.Mathieu M, Petitpas I, Navaza J, Lepault J, Kohli E, Pothier P, Prasad BV, Cohen J, Rey FA (2001) Atomic structure of the major capsid protein of rotavirus: implications for the architecture of the virion. Embo J 20(7):1485–1497. doi: 10.1093/emboj/20.7.1485 PubMedCentralPubMedCrossRefGoogle Scholar
- 19.Plascencia-Villa G, Mena JA, Castro-Acosta RM, Fabian JC, Ramirez OT, Palomares LA (2011) Strategies for the purification and characterization of protein scaffolds for the production of hybrid nanobiomaterials. J Chromatogr B 879(15–16):1105–1111. doi: 10.1016/j.jchromb.2011.03.027 CrossRefGoogle Scholar
- 24.Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9(7):676–682. doi: 10.1038/nmeth.2019 PubMedCrossRefGoogle Scholar
- 25.Plascencia-Villa G, Saniger JM, Ascencio JA, Palomares LA, Ramirez OT (2009) Use of recombinant rotavirus VP6 nanotubes as a multifunctional template for the synthesis of nanobiomaterials functionalized with metals. Biotechnol Bioeng 104(5):871–881. doi: 10.1002/bit.22497 PubMedCrossRefGoogle Scholar